Combination antiretroviral therapy effective at reducing HIV resistance in mothers and babies

Oct 27, 2009

In a clinical trial investigating mother-to-child HIV transmission in South Africa published this week in PLoS Medicine, Neil Martinson (of the Perinatal HIV Research Unit, Soweto, South Africa) and colleagues find that adding two other antiretroviral drugs to single dose nevirapine - an antiretroviral drug given to women and newborn children during labor and delivery to prevent transmission - is effective in reducing the drug resistance that nevirapine causes when used by itself.

Such resistance can compromise later treatment regimens that include the same class of drug as nevirapine. The researchers report that the combination drug regimen — which involved the addition of a twice-daily dose of zidovudine and lamivudine over several days following a single-dose of nevirapine — is safe and easy to provide, and effective in reducing subsequent nevirapine resistance in both mothers and those babies that are infec ted despite antiretrovirals.

In a related Perspective, Dara Lehman (of Fred Hutchinson Cancer Research Center, Seattle, Washington) and colleagues, uninvolved with the research, say that assuming that there is not a large amount of lurking resistance not detected by the study, the approach may "strike the right balance of a feasible regimen that minimizes resistance" in resource-poor settings where combination antiretroviral therapy may not be available for longer-term use in pregnancy.

More information: McIntyre JA, Hopley M, Moodley D, Eklund M, Gray GE, et al. (2009) Efficacy of Short-Course AZT Plus 3TC to Reduce Nevirapine Resistance in the Prevention of Mother-to-Child Transmission: A Randomized Clinical Trial. PLoS Med 6(10): e1000172. doi:10.1371/journal.pmed.1000172

Source: Public Library of Science (news : web)

Explore further: Researchers complete ASPIRE Phase III trial of vaginal ring for HIV prevention in women

Related Stories

Breastfeeding now safer for infants of HIV-infected mothers

Feb 04, 2008

An antiretroviral drug already in widespread use in the developing world to prevent the transmission of HIV from infected mothers to their newborns during childbirth has also been found to substantially cut the risk of subsequent ...

Antenatal HIV

Nov 22, 2007

South Africa's Prevention of Mother to Child Transmission (PMTCT) Programme has severe shortcomings that could be doing more harm than good. HIV patients are missing out on opportunities to receive a key intervention namely ...

Recommended for you

CDC examines prevalence of undiagnosed HIV

1 hour ago

(HealthDay)—Many people have undiagnosed HIV, with the prevalence varying by geographic area, according to a report published in the June 26 issue of the U.S. Centers for Disease Control and Prevention's ...

Potential new HIV therapy seen in immune cells

22 hours ago

A research team led by Weill Cornell Medical College scientists has discovered a way to limit replication of the most common form of HIV at a key moment when the infection is just starting to develop. The ...

More secondary schooling reduces HIV risk

Jun 29, 2015

Longer secondary schooling substantially reduces the risk of HIV infection—especially for girls—and could be a very cost-effective way to halt the spread of the virus, according to researchers from Harvard ...

Bill Gates hopeful of AIDS vaccine in 10 years

Jun 26, 2015

Billionaire and philanthropist Bill Gates, who spends millions of dollars on AIDS drug development, said Friday he hoped for a vaccine against the disease within the next decade as a cure remains far off.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.